Want to see ES:CBAV full AI Analyst Report?
CBAV Stock Chart & Stats
€58.20
€0.60(1.03%)
At close: 4:00 PM EDT
€58.20
€0.60(1.03%)
Day’s Range― - ―
52-Week Range€40.10 - €62.00
Previous CloseN/A
Volume38.00
Average Volume (3M)2.20K
Market Cap
€981.47M
Enterprise Value€882.45
Total Cash (Recent Filing)€51.59M
Total Debt (Recent Filing)€9.90M
Price to Earnings (P/E)21.9
Beta0.51
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.56%
Share Statistics
EPS (TTM)2.79
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio2.92
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)€330.35M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent multi-year revenue growth (2021 €173M to 2025 €302M) reflects expanding clinic scale and rising patient volumes. That durable top-line expansion supports operating leverage, capacity utilization and pricing power, improving medium-term cash flow visibility if volume trends persist.
Strong Operating Cash GenerationOperating cash flow consistently above net income indicates high earnings quality and reliable cash generation. Sustained OCF supports reinvestment, dividends and continued deleveraging without relying on external financing, bolstering financial flexibility over the coming quarters.
Materially Improved Balance SheetSignificant TTM deleveraging and a low debt-to-equity position materially increase financial resilience. Lower leverage reduces interest burden and creates optionality for capex or M&A, enhancing the company’s ability to withstand demand shocks and invest strategically over the medium term.
Bears Say
Margin VolatilityRecent TTM margin shifts versus 2025 indicate variability in gross and operating profitability. Persistent margin volatility can weaken earnings predictability and ROE, and may reflect structural mix changes, pricing pressure or cost dynamics that could persist for several quarters absent corrective action.
Moderate FCF ConversionFree cash flow converting at roughly 60% of net income limits the cash available for dividends, buybacks or accelerated debt reduction. Moderate conversion suggests ongoing reinvestment needs or working-capital swings that could constrain balance sheet improvement and shareholder returns over the medium term.
Dependence On Elective ProceduresRevenue concentration in elective, out-of-pocket procedures creates durable sensitivity to consumer spending, competition and procedure mix. This structural dependency makes top-line and margin outcomes more cyclical and less predictable across economic cycles and could limit steady growth during downturns.
Clinica Baviera News
CBAV FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest stock price was €40.10 and its highest was €62.00 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €981.47M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Jul 29, 2026. The company reported €0.747 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Overvalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA pays a Annually dividend of €1.568 which represents an annual dividend yield of 2.56%. See more information on Clinica Baviera, SA dividends here
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.747 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.024%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in ES:CBAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.